Welcome to our dedicated page for BiomX news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on BiomX stock.
BiomX Inc. (NYSE American: PHGE) is a pioneering clinical-stage microbiome and drug discovery company based in Israel. The company specializes in the development of natural and engineered phage therapies designed to target and destroy harmful bacteria associated with chronic diseases such as inflammatory bowel disease (IBD), colorectal cancer, primary sclerosing cholangitis, and chronic pulmonary infections in cystic fibrosis (CF) patients.
Utilizing advanced computational and synthetic biology research from globally renowned institutions, including the Weizmann Institute of Science and the Massachusetts Institute of Technology (MIT), BiomX's platforms discover and validate proprietary bacterial targets. Their flagship product candidate, BX004, aims to treat chronic pulmonary infections caused by Pseudomonas aeruginosa in CF patients. This program has shown promising clinical results, achieving positive outcomes in both safety and efficacy in Part 2 of a Phase 1b/2a trial, with results expected to be published in November 2023. BX004 has been granted Fast Track designation by the FDA.
In addition to its CF program, BiomX has expanded its pipeline through a recent merger with Adaptive Phage Therapeutics (APT), adding BX211, a personalized phage treatment for diabetic foot osteomyelitis (DFO) caused by Staphylococcus aureus. This merger has bolstered BiomX's capabilities and financial resources, enabling the company to advance its clinical pipeline effectively.
BiomX enjoys strong backing from notable investors such as OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation, Takeda Ventures, Seventure Partners, Mirae Asset Global Investments, and SBI.
For more details on BiomX's ongoing projects and latest developments, visit www.biomx.com.
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focusing on phage therapies targeting specific pathogenic bacteria, announced that it has received a written notification from NYSE American , dated December 10, 2024. The notification confirms that BiomX has regained compliance with all NYSE American continued listing standards. This compliance rectifies the deficiencies noted on May 23, 2024, as outlined in Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide. NYSE American verified that BiomX has met the continued listing standards for two consecutive quarters, in accordance with Section 1009(f) of the Company Guide.
BiomX announced Q3 2024 financial results and clinical program updates. Patient enrollment for BX211 Phase 2 trial in Diabetic Foot Osteomyelitis is complete, with topline results expected in Q1 2025. The BX004 Phase 2b study in Cystic Fibrosis faced manufacturing delays, now resolved, with results expected in H1 2026. Cash balance was $24.7M as of September 30, 2024. R&D expenses increased to $7.3M from $5.6M year-over-year. The company reported net income of $9.6M compared to a net loss of $7.9M in Q3 2023, mainly due to changes in warrant fair value. Cash runway extends into Q4 2025.
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on natural and engineered phage therapies, has scheduled a conference call and webcast for November 14, 2024, at 8:00 a.m. ET. The event will cover the company's third quarter 2024 financial results, business updates, and program developments. Participants can join via phone at 1-877-407-0724 (U.S) or 1-201-389-0898 (International). The webcast will be accessible through the Investors section of BiomX's website.
BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing phage therapies targeting specific pathogenic bacteria, has announced a mandatory separation of its units (PHGE.U). Each unit consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock. The separation will occur on or about October 25, 2024, after which the units will no longer trade on the NYSE American.
Key points:
- Unit holders will receive the underlying shares of Common Stock and Warrants
- The separation is automatic, requiring no action from unit holders
- Warrants will expire on October 28, 2024
- Each warrant allows purchase of one-half share at $115 per share
- Post-separation, Common Stock will trade under the symbol PHGE
BiomX Inc. (NYSE American: PHGE) will present updated data from its Phase 1b/2a study of BX004 for treating cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections at the North American Cystic Fibrosis Conference in Boston. The findings will be showcased in a poster session on September 27, 2024, and discussed in a workshop on September 28, 2024.
Key results include:
- Greater reduction in P. aeruginosa colony-forming units in subjects receiving BX004-A compared to placebo
- 14% of BX004-A recipients had negative P. aeruginosa sputum culture at treatment end, versus 0% for placebo
- Improved lung function (FEV1) in a subgroup of BX004-A recipients (+5.66%) compared to placebo (-3.23%)
The study's six-month follow-up has been completed for all subjects.
BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing novel phage therapies targeting specific pathogenic bacteria, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel.
Key details include:
- CEO Jonathan Solomon will present a corporate overview
- Presentation Date: September 9, 2024
- Time: Available on-demand from 7:00 AM ET
- Webcast link provided for virtual attendance
- Replay available on BiomX's website for 90 days
Mr. Solomon will also be available for one-on-one meetings during the conference. Interested parties can register and request meetings through the provided link.
BiomX Inc. (NYSE American: PHGE) will present positive Phase 1b/2a clinical trial data for BX004, a novel phage therapy targeting Pseudomonas aeruginosa in cystic fibrosis patients, at the European Respiratory Society Congress 2024. The study demonstrated favorable safety and notable microbiologic and clinical efficacy, even in patients on standard care treatment. Key findings include:
1. Greater reduction in P. aeruginosa colony-forming units in treated subjects vs. placebo
2. 14% of treated subjects had negative P. aeruginosa sputum culture at treatment end
3. Improved lung function in a subgroup of treated patients
4. No treatment-related phage resistance or serious adverse events
BiomX CEO Jonathan Solomon expressed encouragement about the results, highlighting the potential of their novel approach in treating cystic fibrosis.
BiomX Inc. (NYSE American: PHGE) has announced a 1-for-10 reverse stock split of its common stock, effective August 26, 2024. The stock will continue trading under the symbol 'PHGE' with a new CUSIP number. This decision follows stockholder approval on July 9, 2024, and final ratio determination by the Board on August 8, 2024. The split will reduce outstanding shares from approximately 178,958,447 to 17,895,845.
Key points:
- Proportional adjustments will be made to equity awards, warrants, convertible preferred stock, and stock incentive plans
- Outstanding units will also undergo a 1-for-10 reverse split, trading under 'PHGE U'
- No fractional shares will be issued; stockholders entitled to fractional shares will receive an additional fraction to round up
- The split won't alter stockholders' percentage ownership, except for minor fractional share adjustments
BiomX Inc. (NYSE American: PHGE) has announced a 1-for-10 reverse stock split of its common stock, effective August 26, 2024. The stock will continue trading under the symbol 'PHGE' with a new CUSIP number. This decision, approved by stockholders on July 9, 2024, will reduce outstanding shares from approximately 178,958,447 to 17,895,845. The reverse split will not alter stockholders' ownership percentages, and fractional shares will be rounded up. No action is required for holders of book-entry or brokerage account shares. The company's units will be proportionally adjusted, maintaining one share and one warrant exercisable for half a share per unit.
BiomX Inc. (NYSE American: PHGE) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. Anticipated readout of topline results for BX211 in Q1 2025 for diabetic foot osteomyelitis treatment.
2. Planned initiation of BX004 Phase 2b trial for cystic fibrosis, with results expected in Q3 2025.
3. Stockholder approval for conversion of Series X Preferred Stock to common stock.
4. Cash balance of $32.7 million as of June 30, 2024, sufficient to fund operations through Q4 2025.
5. Net income of $4.5 million for Q2 2024, compared to a net loss of $6.4 million in Q2 2023.
6. R&D expenses increased to $6.9 million in Q2 2024 from $3.8 million in Q2 2023.
FAQ
What is the current stock price of BiomX (PHGE)?
What is the market cap of BiomX (PHGE)?
What does BiomX Inc. specialize in?
What is BX004?
Who are BiomX's research partners?
What recent merger did BiomX complete?
Who are some of BiomX's investors?
What are some of BiomX's current projects?
Where is BiomX Inc. based?
What technological platforms does BiomX use?
When can we expect results for BX004 Phase 1b/2a trial?
How can I get more information about BiomX?
